SCHEMBL7669733

SCHEMBL7669733

CC(C)(C)OC(=O)CNS(=O)(=O)c1ccc(NC(=O)c2cccs2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.63
MAPT P10636 9/20 0.58
KMT2A Q03164 8/20 0.58
SMN1; SMN2 Q16637 8/20 0.58
MEN1 O00255 7/20 0.58
ALDH1A1 P00352 2/20 0.58
NPSR1 Q6W5P4 2/20 0.56
TSHR P16473 1/20 0.56
TDP1 Q9NUW8 2/20 0.55
PKM P14618 1/20 0.55
NPC1 O15118 6/20 0.52
RAB9A P51151 6/20 0.52
TP53 P04637 2/20 0.52
HTT P42858 2/20 0.52
POLB P06746 1/20 0.52
MAPK1 P28482 1/20 0.52
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
USP2 O75604 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7673541 0.83 LMNA (0.69) LMNAMAPTKMT2ASMN1; SMN2MEN1
SCHEMBL7582747 0.82 LMNA (0.65) LMNAKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL7667947 0.80 NPC1 (0.53) LMNAKMT2ASMN1; SMN2ALDH1A1NPC1
SCHEMBL7674757 0.80 SMN1; SMN2 (0.54) LMNAKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL7663139 0.80 POLB (0.62) LMNAKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL7663740 0.80 ALDH1A1 (0.65) LMNAKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL7584228 0.80 MAPT (0.57) LMNAMAPTKMT2ASMN1; SMN2MEN1
SCHEMBL7669640 0.79 GHSR (0.53) LMNAMAPTKMT2AMEN1ALDH1A1
SCHEMBL7671600 0.79 ALDH1A1 (0.51) LMNAKMT2ASMN1; SMN2MEN1ALDH1A1
SCHEMBL7670521 0.79 MEN1 (0.57) LMNAKMT2ASMN1; SMN2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed